These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Acquired EML4-ALK fusion and EGFR C797S in cis mutation as resistance mechanisms to osimertinib in a non-small cell lung cancer patient with EGFR L858R/T790M. Wang LS; Chen SQ; Zhong X; Jiao XD; Liu K; Qin BD; Wu Y; Ling Y; Duan XP; Zang YS Anticancer Drugs; 2023 Nov; 34(10):1146-1150. PubMed ID: 36728908 [TBL] [Abstract][Full Text] [Related]
44. Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma. Schneeberger VE; Ren Y; Luetteke N; Huang Q; Chen L; Lawrence HR; Lawrence NJ; Haura EB; Koomen JM; Coppola D; Wu J Oncotarget; 2015 Mar; 6(8):6191-202. PubMed ID: 25730908 [TBL] [Abstract][Full Text] [Related]
45. Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations. Lazzara MJ; Lane K; Chan R; Jasper PJ; Yaffe MB; Sorger PK; Jacks T; Neel BG; Lauffenburger DA Cancer Res; 2010 May; 70(9):3843-50. PubMed ID: 20406974 [TBL] [Abstract][Full Text] [Related]
46. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer. Fukuda K; Otani S; Takeuchi S; Arai S; Nanjo S; Tanimoto A; Nishiyama A; Naoki K; Yano S Cancer Sci; 2021 Sep; 112(9):3784-3795. PubMed ID: 34145930 [TBL] [Abstract][Full Text] [Related]
47. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. Costa DB; Halmos B; Kumar A; Schumer ST; Huberman MS; Boggon TJ; Tenen DG; Kobayashi S PLoS Med; 2007 Oct; 4(10):1669-79; discussion 1680. PubMed ID: 17973572 [TBL] [Abstract][Full Text] [Related]
48. Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer. Zhu VW; Klempner SJ; Ou SI Trends Cancer; 2019 Nov; 5(11):677-692. PubMed ID: 31735287 [TBL] [Abstract][Full Text] [Related]
49. Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non-small cell lung cancer. Akazawa Y; Saito Y; Yoshikawa T; Saito K; Nosaka K; Shimomura M; Mizuno S; Nakamoto Y; Nakatsura T Cancer Sci; 2020 Aug; 111(8):2736-2746. PubMed ID: 32391625 [TBL] [Abstract][Full Text] [Related]
50. Management and future directions in non-small cell lung cancer with known activating mutations. Gerber DE; Gandhi L; Costa DB Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124 [TBL] [Abstract][Full Text] [Related]